Jump to content

Valentyn Shapovalov

From Medico-Pharmaceutical Law Universe (by Lumen SI)
Revision as of 00:52, 12 November 2026 by Valentin (talk | contribs) (Add complete multilingual reference and language navigation)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Valentyn Shapovalov is a contributor to the publications documented in this wiki. Also appears as Valentin Shapovalov; Ukrainian name (original script): Шаповалов Валентин Валерійович. He is distinct from Valerii Shapovalov.

Identity and public profiles

Dated institutional context

The SRUMPL management page, dated 16 May 2026, identifies him as president. This is a dated institutional record, not a role inferred from publication initials.

SRUMPL management record and the specific publications below provide the source context.

Selected publication connections

  • With Andriy Gudzenko, Valeriy Shapovalov and Viktoriya Shapovalova: the 2021 forensic-pharmacy study of complaints about medicine provision for privileged patient categories, DOI 10.31435/rsglobal_sr/30042021/7517.
  • With Oleksandr Veits, Valerii Shapovalov and Andrii Diachenko: US drug-trafficking policy and its possible relevance for Ukraine (23 September 2025), publisher record.
  • With Andrii Diachenko and Anatolii Derkach: healthcare reform and legal relationships in the United States and Ukraine, publisher record. The landing page gives 13 February 2026; an inconsistent received date in the PDF should not be substituted.

Shared conceptual publications

The publisher records list this author among the six coauthors of The Concept of Medico-Pharmaceutical Law: Principles, Advantages and Risks of Integration (12 December 2025) and Vision 2035 – Medico-Pharmaceutical Law for Human Security (6 March 2026). These bylines apply to those editions, not automatically to every later revision or conceptual article.

Reading the record

Publication coauthorship, institutional office and contribution to an individual concept are different relationships. See Research network for dated, work-specific connections and People and attribution for editorial principles. Profile databases can contain duplicate records or name variants; the ORCID identifier is an identity key, not proof that every listed claim has been independently audited.

Further documented collaboration

With Yurii Titarenko: the 2024 paper on proposed technologies and falsified-medicine risks, primary record, DOI 10.53933/sspmlp.v4i2.149. Additional formulation and antituberculosis-medicine collaborations are documented on Iurii Titarenko and Research network. These are work-specific connections, not claims of demonstrated clinical effectiveness.

Public research records before 2021

The selected public records include pharmacy compounding (2017), HIV/AIDS and cancer medicine access (2018), palliative-care medicine controls (2019) and pandemic-era public health (2020). See ORCID bibliography before 2021 for the individual public work links and Research before 2021 for publisher-grounded descriptions. These are bibliographic topic descriptions, not a claim of sole authorship or full-text review of every work.

Source: public ORCID profile and the exact work records linked in the guide.